Osteoporosis

Rheumatic Disease Clinics of North America

Volumn 33, Issue 1, 2007, Pages 149-176

  Simon, Lee S ^a  

^a BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALENDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; CALCITONIN; CALCIUM; ESTROGEN; ETIDRONIC ACID; FLUORIDE SODIUM; IBANDRONIC ACID; PAMIDRONIC ACID; PARATHYROID HORMONE; RALOXIFENE; RISEDRONIC ACID; STRONTIUM RANELATE; TILUDRONIC ACID; VITAMIN D;

BONE MASS; CLINICAL FEATURE; DIARRHEA; DIFFERENTIAL DIAGNOSIS; DRUG INDUCED HEADACHE; FLUSHING; HUMAN; LABORATORY TEST; NAUSEA; OSTEOPOROSIS; PATHOPHYSIOLOGY; PRIORITY JOURNAL; RADIODIAGNOSIS; RECOMMENDED DRUG DOSE; REVIEW; SIDE EFFECT;

BONE DENSITY; BONE REMODELING; BONE RESORPTION; CALCITONIN; ESTROGEN REPLACEMENT THERAPY; FRACTURES, BONE; HUMANS; ORGANOMETALLIC COMPOUNDS; OSTEOCLASTS; OSTEOPOROSIS; THIOPHENES;

EID: 33947178566     PISSN: 0889857X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.rdc.2006.12.005     Document Type: Review

References (232)

1. Rodan G.A. Introduction to bone biology. Bone 13 (1992) S3
2. Robey P.G. The biochemistry of bone. Endocrinol Metab Clin North Am 18 (1989) 859
3. Heinegard D., Hultenby K., Oldberg A., et al. Macromolecules in bone matrix. Connect Tissue Res 21 (1989) 3
4. Bork P. The modular architecture of vertebrate collagens. FEBS Lett 307 (1992) 49
5. Krane S.M., and Simon L.S. Organic matrix defects in metabolic and related bone diseases. In: Veis A. (Ed). The chemistry and biology of mineralized connective tissues (1981), Elsevier Science, New York
6. Brown JP, Delmas PD, Malaval L, et al. Serum bone GLA-protein: a specific marker of bone formation in postmenopausal osteoporosis. Presented at the Proceedings of the Copenhagen International Symposium on Osteoporosis. Glostrop Hospital (Denmark), 1984.
7. Lian J.B., Coutts M., and Canalis E. Studies of hormonal regulation of osteocalcin synthesis in cultured fetal rat calvariae. J Biol Chem 260 (1985) 8706
8. Triffitt J.T. Plasma proteins present in human cortical bone: enrichment of the α2HS- glycoprotein. Calcif Tissue Res 22 (1976) 27
9. Ashton B.A., and Smith R. Plasma α2HS-glycoprotein concentrations in Paget's disease of bone: its possible significance. Clin Sci 58 (1980) 435
10. Franzen A., and Heinegard D. Isolation and characterization of two sialoproteins present only in bone calcified matrix. Biochem J 232 (1985) 715
11. Sage E.H., and Bornstein P. Extracellular proteins that modulate cell-matrix interactions, SPARC, tenascin, and thrombospondin. J Biol Chem 266 (1991) 14831
12. Baron R. Polarity and membrane transport in osteoclasts. Connect Tissue Res 20 (1988) 109
13. Suda T., Takahashi N., and Martin T.J. Modulation of osteoclast differentiation. Endocr Rev 13 (1992) 66
14. Aubin J.E. Osteoclast adhesion and resorption: the role of podosomes. J Bone Miner Res 7 (1992) 365
15. Blair H.C., Teitelbaum S.L., Ghiselli R., et al. Osteoclast bone resorption by a polarized vacuolar proton pump. Science 245 (1989) 855
16. Chatterjee D., Chakraborty M., and Leit M. Sensitivity to vanadate and isoforms of subunits A and B distinguish the osteoclast proton pump from other vacuolar H + ATPases. Proc Natl Acad Sci U S A 89 (1992) 6257
17. Jones S.J., Hogg N.M., Shapiro I.M., et al. Cells with Fc receptors in the cell layer next to osteoblasts and osteoclasts in bone. Metab Bone Dis Relat Res 2 (1981) 357
18. Canalis E., McCarthy T.L., and Centrella M. Growth factors and cytokines in bone cell metabolism. Annu Rev Med 42 (1991) 17
19. Gravallese E.M., Galson D.L., Goldring S.R., et al. The role of TNF-receptor family members and other TRAF-dependent receptors in bone resorption. Arthritis Res 3 (2001) 6-12
20. Jilka R.L., Hangoc G., Girasole G., et al. Increased osteoclast development after estrogen loss: mediation by interleukin-6. Science 257 (1992) 88
21. Roodman G.D., Kurihara N., Ohsaki Y., et al. Interleukin 6: a potential autocrine/paracrine factor in Paget's disease of bone. J Clin Invest 89 (1992) 46
22. Passeri G., Girasole G., Knutson S., et al. Interleukin-11 (IL-11): a new cytokine with osteoclastogenic and bone resorptive properties and a critical role in PTH and 1,25(OH)2D3-induced osteoclast development. J Bone Miner Res 7 (1992) S110
23. Raisz L.G., and Kream B.E. Regulation of bone formation. N Engl J Med 309 (1983) 29
24. Parfitt A.M. Surface specific bone remodeling in health and disease. In: Kleerekopper M., and Krane S.M. (Eds). Clinical disorders of bone and mineral metabolism (1989), Mary Ann Liebert, New York
25. Chambers T.J., McSheehy P.M.J., Thomson B.M., et al. The effect of calcium-regulating hormones and prostaglandins on bone resorption by osteoclasts disaggregated from neonatal rabbit bones. Endocrinology 60 (1985) 234
26. Mundy G.R., Shapiro J.L., Bandelin J.G., et al. Direct stimulation of bone resorption by thyroid hormones. J Clin Invest 58 (1976) 529
27. McCarthy T.L., Centrella M., and Canalis E. Regulatory effects on insulin-like growth factor I and II on bone collagen synthesis in rat calvarial cultures. Endocrinology 124 (1989) 301
28. Hock J.M., and Fonseca J. Anabolic effect of human synthetic parathyroid hormone-(1-34) depends on growth hormone. Endocrinology 127 (1990) 1804
29. Lin H., Harris T.L., Flannery M.S., et al. Expression cloning of an adenylate cyclase-coupled calcitonin receptor. Science 254 (1991) 1022
30. Gorn A., Lin H.Y., Yamin M., et al. Cloning, characterization, and expression of a human calcitonin receptor from an ovarian carcinoma cell line. J Clin Invest 90 (1992) 1726
31. Johnson L.C. The kinetics of skeletal remodeling. A further consideration of the theoretical biology of bone. Birth Defects 2 (1966) 66
32. Frost H.M. Bone remodeling and its relationship to metabolic bone diseases (1973), Charles C. Thomas, Springfield (IL)
33. Parfitt A.M. The coupling of bone formation: a critical analysis of the concept and of its relevance to the pathogenesis of osteoporosis. Metab Bone Dis Relat Res 4 (1982) 1
34. Parfitt AM, Kleerehoper M. Diagnostic value of bone histomorphometry and comparison on histologic measurements and biochemical indices of bone remodeling. In: Christiansen C, Arnaud CD, Nordin BEC, et al, editors. Proceedings of the Copenhagen International Symposium on Osteoporosis, Aalborg Stiftsbogtrykkeri, Denmark, 1984. p. 111.
35. Riggs B.L., and Melton L.J. Involutional osteoporosis. N Engl J Med 314 (1986) 1676
36. Riggs B.L., and Melton L.J. Evidence for two distinct syndromes of involutional osteoporosis. Am J Med 75 (1983) 899
37. Melton L.J., and Riggs B.L. Further characterization of the heterogeneity of the osteoporotic syndromes. In: Kleerekoper M., and Krane S.M. (Eds). Clinical disorders of bone and mineral metabolism (1989), Mary Ann Liebert, New York
38. Marcus R., Kosek J., Pfefferbaum A., et al. Age-related loss of trabecular bone in premenopausal women. A biopsy study. Calcif Tissue Int 35 (1983) 406
39. Avioli L.V., and Lindsay R. The female osteoporotic syndrome(s). In: Avioli L.V., and Krane S.M. (Eds). Metabolic bone disease and clinical related disorders (1990), W.B. Saunders, Philadelphia
40. Nagant de Deuxchaisnes C. The pathogenesis and treatment of involutional osteoporosis. In: Dixon A.S.t.J., Russell R.G.G., and Stamp T.C.B. (Eds). Osteoporosis, a multi-disciplinary problem. Royal Society of Medicine International Congress and Symposium Series No. 55 (1983), Academic Press, London
41. Parfitt A.M., Shih M.-S., Rao D.S., et al. Relationship between bone formation rate and osteoblast surface in aging and osteoporosis: evidence for impaired osteoblast recruitment in pathogenesis. J Bone Miner Res 7 Suppl 1 (1992) S116
42. Riggs B.L., and Melton L.J. The prevention and treatment of osteoporosis. N Engl J Med 327 (1992) 620
43. Parfitt A.M. Bone remodeling: relationship to the amount and structure of bone, and the pathogenesis and prevention of fractures. In: Riggs B.L., and Melton L.J. (Eds). Osteoporosis: etiology, diagnosis, and management (1988), Raven Press, New York
44. Parfitt A.M., Mathews C.H.E., Villanueva A.R., et al. Relationships between surface, volume, and thickness of iliac trabecular bone in aging and in osteoporosis: implications for the microanatomic and cellular mechanisms of bone loss. J Clin Invest 72 (1983) 1396
45. Lukert B.P., and Raisz L.G. Glucocorticoid-induced osteoporosis: pathogenesis and management. Ann Intern Med 112 (1990) 352-364
46. Stavros C.M., and Jilka R.L. Bone marrow, cytokines, and bone remodeling: emerging insights into the pathophysiology of osteoporosis. N Engl J Med 332 (1995) 305-311
47. Hurwitz M.C. Cytokines and estrogen in bone: anti-osteoporotic effects. Science 260 (1993) 623
48. Cummings S.R., Nevitt M.C., Browner W.S., et al. Risk factors for hip fracture in white women. N Engl J Med 332 (1995) 767-773
49. Bauer D.C., Browner W.S., Cauley J.A., et al. Factors associated with appendicular bone mass in older women. Ann Intern Med 118 (1993) 657-665
50. Prince R.L., Smith M., Dick I.M., et al. Prevention of postmenopausal osteoporosis. A comparative study of exercise, calcium supplementation, and hormone-replacement therapy. N Engl J Med 325 (1991) 1189-1195
51. Pacifici R. Is there a causal role for IL-1 in postmenopausal bone loss?. Calcif Tissue Int 50 (1992) 295
52. Girasole G., Jilka R.L., Passeri G., et al. 17β-Estradiol inhibits interleukin-6 production by bone marrow-derived stromal cells and osteoblasts in vitro: a potential mechanism for the antiosteoporotic effect of estrogens. J Clin Invest 89 (1992) 883
53. Chaudhary L.R., Spelsberg T.C., and Riggs B.L. Production of various cytokines by normal human osteoblast-like cells in response to interleukin-1β and tumor necrosis factor-α: lack of regulation by 17β-estradiol. Endocrinology 130 (1992) 2528
54. Rickard D., Russel G., and Gowen M. Oestradriol inhibits the release of tumor necrosis factor but not interleukin 6 from adult human osteoblasts in vitro. Osteoporos Int 2 (1992) 94
55. Keeting P.E., Rifas L., Harris S.A., et al. Evidence for interleukin-1β production by cultured normal human osteoblast-like cells. J Bone Miner Res 6 (1991) 827
56. Oursler M.J., Cortese C., Keeting P., et al. Modulation of transforming growth factor-β production in normal human osteoblast-like cells by 17β-estradiol and parathyroid hormone. Endocrinology 129 (1991) 3313
57. Mbalaviele G., Orcel P., Bouizar Z., et al. Transforming growth factor-β enhances calcitonin-induced cyclic AMP production and the number of calcitonin receptors in long-term cultures of human umbilical cord blood monocytes in the presence of 1,25- dihydroxycholecalciferol. J Cell Physiol 152 (1992) 486
58. Schneider H.G., Michelangeli V.P., Frampton R.J., et al. Transforming growth factor-β modulates receptor binding of calciotropic hormones and G protein-mediated adenylate cyclase responses in osteoblast-like cells. Endocrinology 131 (1992) 1383
59. Knappe V., Raue F., Pfeilschifter J., et al. Tumor necrosis factor-alpha inhibits the stimulatory effect of the parathyroid hormone-related protein on cyclic AMP formation in osteoblast-like cells via protein kinase-C + blind E. Biochem Biophys Res Commun 182 (1992) 341
60. Takahashi N., Udagawa N., Akatsu T., et al. Role of colony-stimulating factors in osteoclast development. J Bone Miner Res 6 (1991) 977
61. Melton L.J., Cummings S.R., and Johnston C.C. Heterogeneity of age-related fractures: implications for epidemiology. Bone Miner 2 (1987) 321
62. Stevenson J.C., Hillyard C.J., MacIntyre I., et al. A physiological role for calcitonin: protection of the maternal skeleton. Lancet 2 (1979) 769
63. Deftos L.J., Weissman M.H., Williams G.W., et al. Influence of age and sex on plasma calcitonin in human beings. N Engl J Med 302 (1980) 1351
64. Taggart H.M., Chestnut C.H., Ivey J.L., et al. Deficient calcitonin response to calcium stimulation in postmenopausal osteoporosis. Lancet 1 (1982) 475
65. Tiegs R.D., Body J.J., Barta J.M., et al. Secretion and metabolism of monomeric human calcitonin: effects of age, sex, and thyroid damage. J Bone Miner Res 1 (1986) 339
66. Melton L.J., Wahner H.W., Richelson L.S., et al. Osteoporosis and the risk of hip fracture. Am J Epidemiol 124 (1986) 154
67. Whyte M.P., Bergfeld M.A., Murphy W.A., et al. Postmenopausal osteoporosis: a heterogeneous disorder as assessed by histomorphometric analysis of iliac crest bone from untreated patients. Am J Med 72 (1982) 193
68. Cummings S.R., Rubin S.M., and Black D. The future of hip fractures in the United States: numbers, costs, and potential effects of postmenopausal estrogen. Clin Orthop 252 (1990) 163
69. Finklestein J.S., Neer R.M., Biller B.M.K., et al. Osteopenia in men with a history of delayed puberty. N Engl J Med 326 (1992) 600
70. Prior J.C., Vigna Y.M., Schechter M.T., et al. Spinal bone loss and ovulatory disturbances. N Engl J Med 323 (1990) 1221
71. Klibanski A., Neer R.M., Beitins I.Z., et al. Decreased bone density in hyperprolactinemic women. N Engl J Med 303 (1980) 1511
72. Hartwell D., Riis B.J., and Christiansen C. Changes in vitamin D metabolism during natural and medical menopause. J Clin Endocrinol Metab 71 (1990) 127
73. Villareal D.T., Civitelli R., Chines A., et al. Subclinical vitamin D deficiency in post- menopausal women with low vertebral bone mass. J Clin Endocrinol Metab 72 (1992) 628
74. Gallagher J.C., Riggs B.L., Eisman J., et al. Intestinal calcium absorption and serum vitamin D metabolites in normal subjects and osteoporotic patients: effect of age and dietary calcium. J Clin Invest 64 (1979) 729
75. Slovik D.M., Adams J.S., Neer R.M., et al. Deficient production of 1,25-dihydroxyvitamin D in elderly osteoporotic patients. N Engl J Med 305 (1981) 372
76. Riggs B.L., Hamstra A., and DeLuca H.F. Assessment of 25-hydroxyvitamin D 1α-hydroxylase reserve in postmenopausal osteoporosis by administration of parathyroid extract. J Clin Endocrinol Metab 53 (1981) 833
77. Kanis J.A., and Pitt F.A. Epidemiology of osteoporosis. Bone 13 Suppl (1992) 7
78. Armamonto-Villareal R., Villareal D.T., Avioli L.V., et al. Estrogen status and hereditary are major determinants of premenopausal bone mass. J Clin Invest 90 (1992) 2464
79. Cummings S.R. Are patients with hip fractures more osteoporotic? Review of the evidence. Am J Med 78 (1985) 487
80. Johnston C.C., and Slemenda C.W. Risk prediction of osteoporosis: a theoretic overview. Am J Med 91 Suppl 5B (1991) 47
81. Kelsey J.L., Browner W.S., Seeley D.G., et al. Risk factors for fractures of the distal forearm and proximal humerus. Am J Epdemiol 135 (1992) 477
82. Bell N.H., Shary J., Stevens J., et al. Demonstration that bone mass is greater in black than in white children. J Bone Miner Res 6 (1991) 719
83. Gilsanz V., Roe T.F., Mora S., et al. Changes in vertebral bone density in black girls and white girls during childhood and puberty. N Engl J Med 325 (1991) 1597
84. Sebastian A., Harris S.T., Ottaway J.H., et al. Improved mineral balance and skeletal metabolism in postmenopausal women treated with potassium carbonate. N Engl J Med 330 (1994) 1776-1781
85. Daniell H.W. Osteoporosis of the slender smoker: vertebral compression fractures and loss of metacarpal cortex in relation to postmenopausal cigarette smoking and lack of obesity. Arch Intern Med 136 (1976) 298
86. Seeman E., Melton L.J., O'Fallon W.M., et al. Risk factors for spinal osteoporosis in men. Am J Med 75 (1983) 977
87. Jensen J., Christiansen C., and Rodbro P. Cigarette smoking, serum estrogens, and bone loss during hormone-replacement therapy early after menopause. N Engl J Med 313 (1985) 973
88. Aloia J.F., Cohn S.H., Vaswani A., et al. Risk factors for postmenopausal osteoporosis. Am J Med 78 (1985) 95
89. Spencer H., Rubio N., Rubio E., et al. Chronic alcoholism: frequently overlooked cause of osteoporosis in men. Am J Med 80 (1986) 393
90. Pocock N.A., Eisman J.A., Hopper J.L., et al. Genetic determinants of bone mass in the adult. J Clin Invest 80 (1987) 706-710
91. Christian J.C., Yu P.-L., Slemenda C.W., et al. Heritability of bone mass: a longitudinal study in aging male twins. Am J Hum Genet 44 (1989) 429-433
92. Cooper G.S., and Umbach D.M. Are vitamin D receptor polymorphisms associated with bone mineral density? A meta-analysis. J Bone Miner Res 11 (1996) 1841-1849
93. Frame B., and Nixon R.K. Bone-marrow mast cells in osteoporosis of aging. N Engl J Med 279 (1968) 626
94. Ramos-Remus C., Sibley J., and Russell A.S. Steroids in rheumatoid arthritis: the honeymoon revisited. J Rheumatol 19 (1992) 667
95. Nagant de Deuxchaisnes C., Devogelaer J.P., Esselinckx W., et al. The effect of low dosage glucocorticoids on bone mass in rheumatoid arthritis: a cross-sectional and longitudinal study using single photon absorptiometry. In: Avioli L.V., Gennari C., and Imbimbo B. (Eds). Glucocorticoid effects and their biological consequences (1982), Plenum Press, New York
96. Baylink D.J. Glucocorticoid-induced osteoporosis. [editorial]. N Engl J Med 309 (1983) 306
97. Bressot C., Meunier P.J., Chapuy M.C., et al. Histomorphometric profile, pathophysiology, and reversibility of corticosteroid-induced osteoporosis. Metab Bone Dis Relat Res 1 (1979) 303
98. Hahn T.J., Halstead L.R., Teitelbau S.L., et al. Altered mineral metabolism in glucocorticoid-induced osteopenia: effect of 25-hydroxyvitamin D administration. J Clin Invest 64 (1979) 655
99. Villareal D.T., Civitelli R., Genari C., et al. Is there an effective treatment for glucocorticoid-induced osteoporosis?. Calcif Tissue Int 49 (1991) 141
100. American College of Rheumatology Task Force on Osteoporosis Guidelines. Recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis. Arthritis Rheum 39 (1996) 1791-1801
101. Buckley L.M., Leib E.S., Cartularo K.S., et al. Calcium and vitamin D3 supplementation prevents bone loss in the spine secondary to low-dose corticosteroids in patients with rheumatoid arthritis. Ann Intern Med 125 (1996) 961-968
102. Cauley J.A., Cummings S.R., Seeley D.G., et al. Effects of thiazide diuretic therapy on bone mass, fractures, and falls. Ann Intern Med 118 (1993) 666
103. Laan R.F.J.M., van Riel P.L.C.M., van de Putte L.V.B.A., et al. Low dose prednisone induces rapid reversible axial bone loss in patients with rheumatoid arthritis. A randomized, controlled study. Ann Intern Med 119 (1993) 963-968
104. Caldwell J.R., and Furst D.E. The efficacy and safety of low-dose corticosteroids for rheumatoid arthritis. Semin Arthritis Rheum 21 (1991) 1
105. Joffe I., and Epstein S. Osteoporosis associated with rheumatoid arthritis: pathogenesis and management. Semin Arthritis Rheum 20 (1991) 256
106. Riis B., Thomsen K., and Christiansen C. Does calcium supplementation prevent post-menopausal bone loss?. N Engl J Med 316 (1987) 173
107. Vedi S., Compston J.E., Webb A., et al. Histomorphometric analysis of bone biopsies from the iliac crest of normal British subjects. Metab Bone Dis Relat Res 4 (1982) 231
108. Chavassieux P.M., Arlot M.E., and Meunier P.J. Intermethod variation in bone histomorphometry: comparison between manual and computerized methods applied to iliac bone biopsies. Bone 6 (1985) 221
109. Reeve J., Arlot M.E., Chavassieux P.M., et al. The assessment of bone formation and bone resorption in osteoporosis: a comparison between tetracycline-based iliac histomorphometry and whole body 85Sr kinetics. J Bone Miner Res 2 (1987) 479
110. Recker R.R., Kimmel D.B., Parfitt A.M., et al. Static and tetracycline-based bone histomorphometric data from 34 normal postmenopausal females. J Bone Miner Res 3 (1988) 133
111. Taylor A.K., Lueken S.A., Libanati C., et al. Biochemical markers of bone turnover for the clinical assessment of bone metabolism. Clin Rheum Dis 20 (1994) 589
112. Charles P., Hasling C., Risteli L., et al. Assessment of bone formation by biochemical markers in metabolic bone disease: separation between osteoblastic activity at the cell and tissue level. Calcif Tissue Int 51 (1992) 406
113. Eriksen E.F., Charles P., Melsen F., et al. Serum markers of type I collagen formation and degradation in metabolic bone disease: correlation to bone histomorphometry. J Bone Miner Res 8 (1993) 127
114. Hassager A.C., Risteli J., Risteli L., et al. Diurnal variation in serum markers of type I collagen synthesis and degradation in healthy premenopausal women. J Bone Miner Res 7 (1992) 1307
115. Kushida K., Takahashi M., Kawana K., et al. Comparison of markers for bone formation and resorption in premenopausal and postmenopausal subjects, and osteoporosis patients. J Clin Endocrinol Metab 80 (1995) 2447-2455
116. Delmas P.D. Biochemical markers of bone turnover. J Bone Miner Res 8 Suppl 2 (1993) S549-S555
117. Simon L.S., Krane S.M., Wortman P.D., et al. Serum levels of type I and type III procollagen fragments in Paget's disease of bone. J Clin Endocrinol Metab 58 (1984) 110-120
118. Robins S.P., Black D., Paterson C.R., et al. Evaluation of urinary hydroxypyridinium crosslink measurements as resorption markers in metabolic bone diseases. Eur J Clin Invest 21 (1991) 310
119. Delmas P., Geneyts E., Bertholin A., et al. Immunoassay of pyridinoline crosslink excretion in normal adults and in Paget's disease. J Bone Miner Res 8 (1993) 643-648
120. Kivirikko K.I. Urinary excretion of hydroxyproline in health and disease. Int Rev Connect Tissue Res 5 (1970) 93
121. Weiss P.H., and Klein L. The quantitative relationship of urinary peptide hydroxyproline excretion to collagen degradation. J Clin Invest 48 (1969) 1
122. Parfitt A.M., Simon L., Villanueva A.R., et al. Procollagen type I carboxy-terminal extension peptide in serum as a marker of collagen synthesis in bone. Correlation with iliac bone formation rates and comparison with total alkaline phosphate. J Bone Miner Res 2 (1987) 427
123. Epstein S. Serum and urinary markers of bone remodeling. Endocr Rev 9 (1988) 437
124. Delmas P.D. Clinical use of biochemical markers of bone remodeling in osteoporosis. Bone 13 (1992) S17
125. Uebelhart D., Gineyts E., Chapuy M.-C., et al. Urinary excretion of pyridinium crosslinks: a new marker of bone resorption in metabolic bone disease. Bone Miner 8 (1990) 87
126. Beardsworth L.J., Eyre D.R., and Dickson I.R. Changes with age in the urinary excretion of Lysyl- and hydroxylysylpyridinoline, two new markers of bone collagen turnover. J Bone Miner Res 5 (1990) 671
127. Panigrahi K., Delmas P.D., Singer F., et al. Characteristics of a two-site immunoradiometric assay for human skeletal alkaline phosphatase in serum. Clin Chem 40 (1994) 822-828
128. Black D., Marabani M., Sturrock R.D., et al. Urinary excretion of the hydroxypyridinium cross links of collagen in patients with rheumatoid arthritis. Ann Rheum Dis 48 (1989) 641
129. Harvey R.D., McHardy K.C., Reid I.W., et al. Measurement of bone collagen degradation in hyperthyroidism and during thyroxine replacement therapy using pyridium cross-links as specific urinary markers. J Clin Endocrinol Metab 72 (1991) 1189
130. Reiser K., McCormick R.J., and Rucker R.B. Enzymatic and nonenzymatic crosslinking of collagen and elastin. FASEB J 6 (1992) 2439
131. Greenwald R.A. Monitoring collagen degradation in patients with arthritis. Arthritis Rheum 39 (1996) 1455-1465
132. Cummings S.R., Black D., Ensrud K., et al. Urine markers of bone resorption predict bone loss and fractures in older women: the study of osteoporotic fractures. J Bone Miner Res 11 (1996) S128
133. Ganero P., Hausherr E., Chapuy M.-C., et al. Markers of bone resorption predict fractures in elderly women: the EPIDOS prospective study. J Bone Miner Res 11 (1996) 1531-1538
134. Singh M., Riggs B.L., Beabout J.W., et al. Femoral trabecular-pattern index for evaluation of spinal osteoporosis. Ann Intern Med 77 (1972) 63
135. Meema H.E., and Meema S. Cortical bone mineral density versus cortical thickness in diagnosis of osteoporosis: a roentgenologic-densitometric study. J Am Geriatr Soc 17 (1969) 120
136. Hall F.M., David M.A., and Baran D.T. Bone mineral screening for osteoporosis. N Engl J Med 316 (1987) 212
137. Pouilles J.M., Tremollieres F., Louvet J.P., et al. Sensitivity of dual-photon absorptiometry in spinal osteoporosis. Calcif Tissue Int 43 (1988) 329
138. Bergot C., Laval-Jeantet A.-M., Preteux F., et al. Measurement of anisotropic vertebral trabecular bone loss during aging by quantitative image analysis. Calcif Tissue Int 43 (1988) 143
139. Kelly T.L., Slovik D.M., Schoenfeld D.A., et al. Quantitative digital radiography versus dual photon absorptiometry of the lumbar spine. J Clin Endocrinol Metab 67 (1988) 839
140. Baran D.R., Kelly A.M., Karellas A., et al. Ultrasound attenuation of the os calcis in women with osteoporosis and hip fractures. Calcif Tissue Int 43 (1988) 138
141. Libanati C.R., Schulz E.E., Shook J.E., et al. Hip mineral density in females with a recent hip fracture. J Clin Endocrinol Metab 74 (1992) 351
142. Johnston C.C., Melton L.J., Lindsay R., et al. Clinical indications for bone mass measurements. A report from the Scientific Advisory Board of the National Osteoporosis Foundation. J Bone Miner Res 4 Suppl (1989) 2
143. Slemenda C.W., Hill S.L., Longcope C., et al. Predictors of bone mass in perimenopausal women. Ann Intern Med 112 (1990) 96
144. Cosman F., Schnitzer M.B., McCann P.D., et al. Relationships between quantitative histological measurements and noninvasive assessments of bone mass. Bone 13 (1992) 237
145. Genant H.K., Ettinger B., Cann C.E., et al. Osteoporosis: assessment by quantitative computed tomography. Orthop Clin North Am 16 (1985) 557
146. Poss P.D., Davis J.W., Vogel J.M., et al. A critical review of bone mass and the risk of fractures in osteoporosis. Calcif Tissue Int 46 (1990) 149-161
147. Sartoris D.J., André M., Resnick C., et al. Trabecular bone density in the proximal femur: quantitative CT assessment. Radiology 160 (1986) 707
148. Ryan P.J., Evans P., Gibson T., et al. Chronic low back pain: comparison of bone SPECT with radiography and CT. Radiology 182 (1992) 849
149. Gonnelli S., Cepollaro C., Agnusdei D., et al. Diagnostic value of ultrasound analysis and bone densitometry as predictors of vertebral deformity in postmenopausal women. Osteoporos Int 5 (1995) 413-418
150. Riggs B.L., Wahner H.W., Dunn W.L., et al. Differential changes in bone mineral density of the appendicular and axial skeleton with aging. J Clin Invest 67 (1981) 328
151. Symmons D.P.M., Van Hemert A.M., Vanderbroncke J.P., et al. A longitudinal study of back pain and radiological changes in the lumber spine of middle aged women. II. Radiographic findings. Ann Rheum Dis 50 (1991) 162
152. Ryan P.J., Evans P., Gibson T., et al. Osteoporosis and chronic back pain: a study with single-photon emission computed tomography bone scintigraphy. J Bone Miner Res 7 (1992) 1455
153. Christiansen C. Consensus development conference on osteoporosis. Am J Med 91 5B (1991) 1S
154. Dawson-Hughes B.D., Dallal G.E., Krall E.A., et al. A controlled trial of the effect of calcium supplementation on bone density in postmenopausal women. N Engl J Med 323 (1990) 878
155. Elders P.J.M., Netelenbos J.C., Lips P., et al. Calcium supplementation reduces vertebral bone loss in perimenopausal women: a controlled trial in 248 women between 46 and 55 years of age. J Clin Endocrinol Metab 73 (1991) 533
156. Reid I.R., Ames R.W., Evans M.C., et al. Effect of calcium supplementation on bone loss in postmenopausal women. N Engl J Med 328 (1993) 460
157. Christiansen C. Prevention and treatment of osteoporosis: a review of current modalities. Bone 13 (1992) S35
158. Bullamore J.R., Gallagher J.C., Wilkinson R., et al. Effect of age on calcium absorption. Lancet 2 (1970) 535
159. Alevizaki C.C., Ikkos D.G., and Singhelakis P. Progressive decrease of true intestinal calcium absorption with age in normal man. J Nucl Med 14 (1973) 760
160. Aloia J.F., Vaswani A., Yeh J.K., et al. Calcium supplementation with and without hormone replacement therapy to prevent postmenopausal bone loss. Ann Intern Med 120 (1994) 97-103
161. Chapuy M.C., Arlot M.E., Duboeuf F., et al. Vitamin D3 and calcium to prevent hip fractures in elderly women. N Engl J Med 327 (1992) 1637-1642
162. Tilyard M.W., Spears G.F.S., Thomson J., et al. Treatment of postmenopausal osteoporosis with calcitriol or calcium. N Engl J Med 326 (1992) 357-362
163. Sambrook P., Birmingham J., Kelley P., et al. Prevention of corticosteroid osteoporosis: a comparison of calcium, calcitriol, and calcitonin. N Engl J Med 328 (1993) 1747-1752
164. Richelson L.S., Heinz W.W., Melton L.J., et al. Relative contributions of aging and estrogen deficiency to postmenopausal bone loss. N Engl J Med 311 (1984) 1273-1275
165. Prior J.C., Vigna Y.M., Barr S.I., et al. Cyclic medroxyprogesterone treatment increases bone density. Am J Med 96 (1994) 521
166. Felson D.T., Zhang Y., Hannah M.T., et al. The effect of postmenopausal estrogen therapy on bone density in elderly women. N Engl J Med 329 (1993) 1141-1146
167. Lafferty F.W., and Fiske M.E. Postmenopausal estrogen replacement: a long term cohort study. Am J Med 97 (1994) 66
168. Cauley J.A., Seely D.G., Ensrud K., et al. Estrogen replacement therapy and fractures in older women. Ann Intern Med 122 (1995) 9-16
169. Grisso J.A., Kelsey J.L., Strom B.L., et al. Risk factors for hip fracture in black women. N Engl J Med 330 (1994) 1555-1559
170. Lindsay R., Hart D.M., Forrest C., et al. Prevention of spinal osteoporosis in oophorectomised women. Lancet 2 (1980) 1151
171. Nachtigall L.E., Nachtigall R.H., Nachtigall R.D., et al. Estrogen replacement therapy 1: a 10-year prospective study in the relationship to osteoporosis. Obstet Gynecol 53 (1979) 277
172. Munk-Jensen N., Nielsen S.P., and Eriksen P.B. Reversal of postmenopausal vertebral bone loss by oestrogen and progestogen: a double blind placebo controlled study. BMJ 296 (1988) 1150
173. Ettinger B., Genant H.K., and Cann C.E. Long-term estrogen replacement therapy prevents bone loss and fractures. Ann Intern Med 102 (1985) 319
174. Kiel D.P., Felson D.T., Anderson J.J., et al. Hip fracture and the use of estrogens in postmenopausal women. N Engl J Med 317 (1987) 1169
175. Naessen T., Persson I., Adami H.-O., et al. Hormone replacement therapy and the risk for the first hip fracture. A prospective, population-based cohort study. Ann Intern Med 113 (1990) 95
176. Paganini-Hill A., Ross R.K., Gerkins V.R., et al. Menopausal estrogen therapy and hip fractures. Ann Intern Med 95 (1981) 28
177. Weiss N.S., Ure C.L., Ballard J.H., et al. Decreased risks of fractures of the hip and lower forearm with postmenopausal use of estrogen. N Engl J Med 303 (1980) 1195
178. Lufkin E.G., Wahner H.W., O'Fallon W.M., et al. Treatment of postmenopausal osteoporosis with transdermal estrogen. Ann Intern Med 117 (1992) 1
179. Adami S., Suppi R., Bertoldo F., et al. Transdermal estradiol in the treatment of postmenopausal bone loss. Bone Miner 7 (1989) 79
180. Lindsay R., Hart D.M., and Clark D.M. The minimum effective dose of estrogen for prevention of postmenopausal bone loss. Obstet Gynecol 63 (1984) 759
181. Ettinger B., Genant H.K., and Cann C.E. Postmenopausal bone loss is prevented by treatment with low-dosage estrogen with calcium. Ann Intern Med 106 (1987) 40
182. Whitehead M.I., Townsend P.T., Pryse-Davies J., et al. Effects of estrogens and progestins on the biochemistry and morphology of the postmenopausal endometrium. N Engl J Med 304 (1981) 1599
183. Christiansen C., and Riis B.J. 17β-estradiol and continuous norethisterone: a unique treatment for established osteoporosis in elderly women. J Clin Endocrinol Metab 71 (1990) 836
184. Grady D., Rubin S.M., Petitti D.B., et al. Hormone therapy to prevent disease and prolong life in postmenopausal women. Ann Intern Med 117 (1992) 1016
185. Steinberg K.K., Thacker S.B., Smith J., et al. A meta-analysis of the effect of estrogen replacement therapy on the risk of breast cancer. JAMA 1 (1991) 265
186. Colditz G.A., Stampfer M.J., Willett W.C., et al. Prospective study of estrogen replacement therapy and risk in breast cancer in postmenopausal women. JAMA 264 (1990) 2648
187. Berkvist L., Adami H.-O., Persson I., et al. The risk of breast cancer after estrogen and estrogen-progestin replacement. N Engl J Med 321 (1989) 293
188. Henderson B.E., Ross R.K., Lobo R.A., et al. Re-evaluating the role of progestogen therapy after the menopause. Fertil Steril 49 Suppl 5 (1988) 9S
189. Schneider D.L., Barrett-Connor E.L., and Morton D.J. Thyroid hormone use and bone mineral density in elderly women. JAMA 271 (1994) 1245-1249
190. Srivastava M., and Deal C. Osteoporosis in elderly: prevention and treatment. Clin Geriatr Med 18 3 (2002) 529-555
191. Montemurro L., Schiraldi G., Fraiolo P., et al. Prevention of corticosteroid-induced osteoporosis with salmon calcitonin in sarcoid patients. Calcif Tissue Int 49 (1991) 71-76
192. Mazzuoli G.F., Passeri M., Gennari C., et al. Effects of salmon calcitonin in postmenopausal osteoporosis: a controlled double-blind clinical study. Calcif Tissue Int 38 (1986) 3
193. Gennari C., Chierichetti S.M., Bigazzi S., et al. Comparative effects on bone mineral content of calcium and calcium plus salmon calcitonin given in two different regimens in postmenopausal osteoporosis. Current Therapeutic Research 38 (1985) 455
194. MacIntyre I., Whitehead B.I., Banks L.M., et al. Calcitonin for prevention of postmenopausal bone loss. Lancet 1 (1988) 900
195. Overgaard K. Effect of intranasal salmon calcitonin therapy on bone mass and bone turnover in early postmenopausal women: a dose response study. Calcif Tissue Int 55 (1994) 82-86
196. Overgaard K., Riis B.J., Christinasen C., et al. Effect of salcotonin given intranasally on early postmenopausal bone loss. BMJ 299 (1989) 477-479
197. Overgaard K., Hansen M.A., Jensen S.B., et al. Effect of salcatonin given intranasally on bone mass and fracture rates in established osteoporosis. BMJ 305 (1992) 556
198. Overgaard K., Hansen M.A., and Christiansen C. Effect of intranasal calcitonin on bone mass and fracture rates in elderly women. A dose-response study. [abstract]. J Bone Miner Res 7 Suppl 1 (1992) S117
199. Gennari C., Agnusdei D., Montagnani M., et al. An effective regimen of intranasal calcitonin in early postmenopausal bone loss. Calcif Tissue Int 50 (1992) 381
200. Reginster J.Y. Effect of calcitonin on bone mass and fracture rates. Am J Med 91 Suppl 5B (1991) 19S
201. Reginster J.Y., Albert A., Lecart M.P., et al. One-year controlled randomised trial of prevention of early postmenopausal bone loss by intranasal calcitonin. Lancet 2 (1987) 1481
202. Overgaard K., Hansen M.A., and Christiansen C. Effect of intranasal calcitonin on bone mass and bone turnover in early postmenopausal women. [abstract]. J Bone Miner Res 7 Suppl 1 (1992) S140
203. Civitelli R., Gonnelli S., Zachei F., et al. Bone turnover in postmenopausal osteoporosis. Effect of calcitonin therapy. J Clin Invest 82 (1988) 1268-1274
204. Lyritis G.P., Tsakalabos S., Magiasis B., et al. Analgesic effect of salmon calcitonin on osteoporotic vertebral fractures. Double-blind, placebo-controlled study. Calcif Tissue Int 49 (1991) 369-372
205. Watts N.B., Harris S.T., Genant H.K., et al. Intermittent cyclical etidronate treatment of postmenopausal osteoporosis. N Engl J Med 323 (1990) 73
206. Struys A., Snelden A.A., and Mulder H. Cyclic etidronate reverses bone loss of the spine and proximal femur in patients with established corticosteroid induced osteoporosis. Am J Med 99 (1995) 235-242
207. Harris S.T., Watts N.B., Jackson R.D., et al. Four-year study of intermittent cyclic etidronate treatment of postmenopausal osteoporosis: three years of blinded therapy followed by one year of open therapy. Am J Med 95 (1993) 557
208. Storm T., Thamsborg G., Steiniche T., et al. Effect of intermittent cyclical etidronate therapy on bone mass and fracture rate in women with postmenopausal osteoporosis. N Engl J Med 322 (1990) 1265-1271
209. Papapoulos S.E., Landman S.O., Bijvoet O.L.M., et al. The use of bisphosphonates in the treatment of osteoporosis. Bone 13 Suppl 1 (1992) S41
210. Seedor G., Quartuccio H.A., and Thompson D.D. The bisphosphonate alendronate (MK-217) inhibits bone loss due to ovariectomy in rats. J Bone Miner Res 6 (1991) 339
211. Liberman U.A., Weiss S.R., Broll J., et al. Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. N Engl J Med 333 (1995) 1437-1443
212. Licata A.A. Bisphosphonate therapy. Am J Med Sci 313 (1997) 1
213. Cohen S.B. An update on bisphosphonates. Curr Rheumatol Rep 6 (2004) 59-65
214. Black D.M., Cummings S.R., Karpf D.B., et al. Randomized trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Lancet 348 (1996) 1535-1541
215. Geusens P., Nijs J., Van der Perre G., et al. Longitudinal effect on tiludronate on bone mineral density, resonant frequency and strength in monkeys. J Bone Miner Res 7 (1992) 599
216. Reginster J.Y., Deroisy R., Denis D., et al. Prevention of postmenopausal bone loss by tiludronate. Lancet 2 (1989) 1469
217. Riggs B.L., Baylink D.J., Kleerekoper M., et al. Incidence of hip fractures in osteoporotic women treated with sodium fluoride. J Bone Miner Res 2 (1987) 123
218. Riggs B.L., Hodgson S.F., O'Fallon W.M., et al. Effect of fluoride treatment on the fracture rate in postmenopausal women with osteoporosis. N Engl J Med 322 (1990) 802
219. Pak C.Y.C., Sakhaee K., Adams-Huet B., et al. Treatment of postmenopausal osteoporosis with slow-release sodium fluoride. Ann Intern Med 123 (1995) 401-408
220. Reeve J., Meunier P.J., Parsons J.A., et al. Anabolic effect of human parathyroid hormone fragment on trabecular bone in involutional osteoporosis: a multicenter trial. BMJ 280 (1980) 1340
221. Reeve J., Bradbeer J.N., Arlot M., et al. hPTH 1-34 treatment of osteoporosis with added hormone replacement therapy: biochemical, kinetic and histological responses. Osteoporos Int 1 (1991) 162
222. Slovik D.M., Neer R.M., and Potts J.T. Short-term effects of synthetic human parathyroid hormone-(1-34) administration on bone mineral metabolism in osteoporotic patients. J Clin Invest 68 (1981) 1261
223. Neer R, Slovik D, Daly M, et al. Treatment of postmenopausal osteoporosis with daily parathyroid hormone plus calcitriol. In: Chritstiansen C, Overgaard K, editor. Osteoporosis 1990: Proceedings of the Third International Symposium on Osteoporosis. Copenhagen (Denmark): Osteopress Aps; 1990.
224. Neer RM, Slovik DM, Doppelt S, et al. The use of parathyroid hormone plus 1,25-dihydroxyvitamin D to increase trabecular bone in osteoporotic men and postmenopausal women. In: Chritstiansen C, Overgaard K, editor. Osteoporosis 1990: Proceedings of the Third International Symposium on Osteoporosis. Copenhagen (Denmark): Osteopress Aps; 1990.
225. Finkelstein J.S., Klibanski A., Schaefer E.H., et al. Parathyroid hormone for the prevention of bone loss induced by estrogen deficiency. N Engl J Med 331 (1994) 1618-1623
226. Horwitz M., Stewart A., and Greenspan S.L. Sequential parathyroid hormone/alendronate therapy for osteoporosis-robbing Peter to pay Paul?. J Clin Endocrinol Metab 85 (2000) 2129-2134
227. Brixen K.T., Christensen P.M., Ejersted C., et al. Teriparatide (biosynthetic human parathyroid hormone 1-34): a new paradigm in the treatment of osteoporosis. Basic Clin Pharmacol Toxicol 94 (2004) 260-270
228. Conn D. New ways with old bones. Osteoporosis researchers look for drugs to replace hormone replacement therapy. Lancet 363 (2004) 786-787
229. Chestnut C.H., Ivey J.L., Gruber H.E., et al. Stanazol in the postmenopausal osteoporosis: therapeutic efficacy and possible mechanisms of action. Metabolism 32 (1983) 571-580
230. Hassager C., Riis B.J., Podenphat J., et al. Nadrolone decanoate treatment of postmenopausal osteoporosis for 2 years and effects of withdrawal. Maturitas 11 (1989) 305-317
231. Meunier P.J., Roux C., Seeman E., et al. The effects of strontium ranelate on the risk of vertebral fracture in women with postmenopausal osteoporosis. N Engl J Med 350 (2004) 459-468
232. Compston J. Prevention of vertebral fractures by strontium ranelate in postmenopausal women with osteoporosis. Osteoporosis Int 16 Suppl 1 (2005) S4-S6